CLINICAL_TRIALS
trial_result
· 2020-09-04
Clinical Trial Update: Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
Summary
Phase 2 trial assessing safety and efficacy of pamrevlumab (FG-3019) in idiopathic pulmonary fibrosis has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kyntra Bio | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2020-09-04